SCHEMBL10169504

SCHEMBL10169504

CC(C)c1cccc(N(C)S(=O)(=O)c2ccc(-c3ccccc3)cc2)c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 5/20 0.59
HSD17B2 P37059 5/20 0.59
CA12 O43570 1/20 0.51
CA9 Q16790 1/20 0.51
HTT P42858 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MEN1 O00255 1/20 0.50
MAPT P10636 1/20 0.50
ALOX12 P18054 1/20 0.50
KMT2A Q03164 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PKM P14618 1/20 0.47
ADAMTS4 O75173 1/20 0.47
NR1H3 Q13133 3/20 0.46
RXRA P19793 1/20 0.44
RXRB P28702 1/20 0.44
RXRG P48443 1/20 0.44
TSHR P16473 1/20 0.44
ATM Q13315 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10169327 0.91 NR1H3 (0.53) HSD17B1HSD17B2CA12CA9HTT
SCHEMBL10169508 0.84 FFAR1 (0.50) HSD17B1HSD17B2CA12CA9HTT
SCHEMBL10169506 0.83 NPC1 (0.60) HSD17B1HSD17B2CA12CA9HTT
SCHEMBL18085884 0.82 LMNA (0.55) HSD17B1HSD17B2CA12CA9HTT
SCHEMBL6794824 0.82 CA12 (0.73) HSD17B1HSD17B2CA12CA9HTT
SCHEMBL24721301 0.80 RXRA (0.53) HSD17B1HSD17B2CA12CA9HTT
SCHEMBL10169507 0.78 HSD17B1 (0.48) HSD17B1HSD17B2HTTKDM4EMEN1
SCHEMBL10169398 0.76 CYP11B1 (0.47) HSD17B1HSD17B2L3MBTL1NR1H3
SCHEMBL10169213 0.76 ALDH1A1 (0.48) CA9HTTKDM4EMEN1MAPT
SCHEMBL19019173 0.76 ALDH1A1 (0.72) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8586751-B2 Nicotinamide compounds useful as kinase modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2013-11-19 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS BRISTOL-MEYERS SQUIBB COMPANY 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120082702-A1 NICOTINAMIDE COMPOUNDS USEFUL AS KINASE MODULATORS NADK, BTK, NAMPT HSD17B1 2692/4885HSD17B2 3012/4885CA12 4838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.